Form 4: Supernus Pharmaceuticals Executive Bhatt Exercises Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Padmanabh P. Bhatt, a Senior VP at Supernus Pharmaceuticals, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan on March 13, 2024.
Summary
- On March 13, 2024, Padmanabh P. Bhatt, Sr. VP of IP and CSO at Supernus Pharmaceuticals, exercised stock options to acquire 26,250 shares at $23.99 and 36,116 shares at $12.98.
- Simultaneously, Bhatt sold 26,250 shares at a weighted average price of $34.1 and 36,116 shares at a weighted average price of $33.48.
- These transactions were executed under a 10b5-1 trading plan adopted on September 7, 2023.
- Following these transactions, Bhatt directly owns 8,570 shares of common stock and 8,750 employee stock options exercisable at $23.99.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider trading activity. It is common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership.
Key Dates
| Date | Description |
|---|---|
| 09/07/2023 | Date of adoption of the 10b5-1 trading plan. |
| 03/13/2024 | Date of the stock option exercise and share sale transactions. |
| 03/15/2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.